Pharmacoeconomic evaluations of CDK4/6 inhibitors plus endocrine therapy for advanced hormone receptor-positive (HR+) and human epidermal growth factor receptor-2 negative (HER2−) breast cancer: a systematic review

BACKGROUND: Hormone receptor-positive (HR+) and human epidermal growth factor receptor-2 negative (HER2−) breast cancer is the most common molecular subtype of breast cancer in many countries, and endocrine therapy remains a mainstay in its treatment. Cyclin-dependent kinase (CDK) 4/6 inhibitors are...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Linhui, Wang, Mengmeng, Luo, Xin, Li, Huan, Shan, Han, Du, Qiong, Zhai, Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8908180/
https://www.ncbi.nlm.nih.gov/pubmed/35280368
http://dx.doi.org/10.21037/atm-21-5110

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8908180/
https://www.ncbi.nlm.nih.gov/pubmed/35280368
http://dx.doi.org/10.21037/atm-21-5110

Ejemplares similares